Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | SAR443216 |
Synonyms | |
Therapy Description |
SAR443216 is a trispecific antibody that binds to ERBB2 (HER2), CD3, and CD28, which potentially activates CD4 and CD8 T cells, resulting in T cell-dependent cellular toxicity and anti-tumor activity against ERBB2 (HER2)-expressing tumors (Cancer Res 2021;81(13_Suppl):Abstract nr 1825). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SAR443216 | SAR-443216|SAR 443216 | CD3 Antibody 92 HER2 (ERBB2) Antibody 72 | SAR443216 is a trispecific antibody that binds to ERBB2 (HER2), CD3, and CD28, which potentially activates CD4 and CD8 T cells, resulting in T cell-dependent cellular toxicity and anti-tumor activity against ERBB2 (HER2)-expressing tumors (Cancer Res 2021;81(13_Suppl):Abstract nr 1825). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05013554 | Phase I | SAR443216 | Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors | Terminated | USA | FRA | ESP | BEL | 2 |